As hemophilia market heats up, Roche confirms 5 Hemlibra patient deaths
fiercepharma | March 28, 2018
After hemophilia patient groups this week posted information about deaths during treatment with Roche's Hemlibra, the drugmaker confirmed that five patients using the drug have died. None of the deaths was determined to be linked to the drug, a Roche spokesperson said. One patient who received Hemlibra under a compassionate use program before it won FDA approval died in 2016, the company said. Two died in 2017 one under a compassionate use program and one in the phase 3 Haven 1 trial. This year, two adults using the treatment died. "Again, the treating physician’s assessment for both patients was that the cause of death was unrelated to Hemlibra," the company spokesperson said. Hemlibra won U.S. approval back in November.